Global cost of cancer projected to exceed $25 Trillion by 2050

Cost of cancer by 2050

Share This Post

Feb 2023: According to data published in JAMA Oncology, the global economic cost of cancer is projected to reach $25,2 trillion in international dollars (INT) between 2020 and 2050.

North America is projected to have the highest cost, and China is projected to have the highest cost per capita. The cancers of the trachea, bronchus, and lung are anticipated to incur the highest costs.

Researchers used a macroeconomic model to make these forecasts. Between 2020 and 2050, they projected the cost of 29 cancers in 204 countries and territories.

The United States ($5,300 billion), China ($6,100 billion), and India ($1,400 billion) will bear the largest economic costs.

Bulgaria (1.42%), Monaco (1.33%), and Montenegro (1.0%) are the countries with the highest projected economic costs as a percentage of gross domestic product. The projected economic cost per capita is greatest in Monaco ($85,230), Ireland ($54,009), and Bermuda ($20,732)

North America is projected to have the highest economic burden from cancer as a proportion of gross domestic product, equivalent to a 0.83 percent annual tax. Europe and Central Asia (0.63%), East Asia and the Pacific (0.59%), and Sub-Saharan Africa (0.24%) follow.

By cancer type, the highest economic cost is projected for:

 

The researchers noted that these cancers account for half of the global economic cost of cancer.

The researchers wrote, “The macroeconomic cost of cancer was found to be substantial and heterogeneously distributed across cancer types, countries, and world regions.” The findings indicate that global efforts to reduce the prevalence of cancer are warranted.

A related editorial highlighted the study’s limitations, including the absence of data for 60 countries, or 7.3% of the total population.

Disclosures: The study authors reported having no conflicts of interest. The editorial author declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original references for a full list of disclosures.

Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. His career is marked by significant contributions to stem cell biology, developmental biology, and innovative research techniques.

Research Highlights

Dr. Mittal's research has focused on several key areas:

1) Cardiovascular Development and Regeneration: He studied coronary vessel development and regeneration using zebrafish models1.

2) Cancer Biology: At Dartmouth College, he developed zebrafish models for studying tumor heterogeneity and clonal evolution in pancreatic cancer.
3) Developmental Biology: His doctoral work at Keio University involved identifying and characterizing medaka fish mutants with cardiovascular defects.

4) Stem Cell Research: He investigated the effects of folic acid on mouse embryonic stem cells and worked on cryopreservation techniques for hematopoietic stem cells.

Publications and Presentations

Dr. Mittal has authored several peer-reviewed publications in reputable journals such as Scientific Reports, Cardiovascular Research, and Disease Models & Mechanisms1. He has also presented his research at numerous international conferences, including the Stanford-Weill Cornell Cardiovascular Research Symposium and the Weinstein Cardiovascular Development Conference.

In summary, Dr. Nishant Mittal is a dedicated and accomplished researcher with a strong track record in cardiovascular and cancer biology, demonstrating expertise in various model systems and a commitment to advancing scientific knowledge through innovative research approaches.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

PiggyBac Transposon System
AI & Technology

PiggyBac Transposon System: A Revolutionary Tool in Cancer Gene Therapy

The PiggyBac Transposon System is revolutionizing genetic engineering in cancer research, especially in CAR T-cell therapy. With its high integration efficiency and large cargo capacity, it provides a powerful, non-viral alternative to traditional gene delivery methods. Learn how PiggyBac is advancing personalized cancer treatment and shaping the future of oncology.

Breakthrough 2025 Treatments for Advanced Breast Cancer
Biotech Innovations

Breakthrough Treatments for Advanced Breast Cancer in 2025

In 2025, advanced breast cancer treatment has entered a new era. Precision medicine and targeted therapies are enabling doctors to tailor care based on genetic profiles. Immunotherapy and antibody-drug conjugates are delivering more effective tumor targeting, while experimental cellular treatments like CAR T-cell therapy show immense promise. These cutting-edge options are transforming outcomes and quality of life for patients facing metastatic breast cancer. Explore the latest innovations driving hope and progress.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

We Are Online! Chat With Us!
Scan the code